|
|
|
|
|
|
|
|
|
05.08.25 - 22:03
|
Cerus Corporation Announces Second Quarter 2025 Financial Results (Business Wire)
|
|
|
Second Quarter Total Revenue of $60.1 Million; Record Product Revenue of $52.4 Million, Up 16% Year-Over-Year
Raising Full-Year 2025 Product Revenue Guidance Range to $200 Million - $203 Million
Conference Call Today at 4:30 pm ETCONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced financial results for the second quarter ended June 30, 2025, and provided a business update.
“With our singular focus to advance blood safety and availability around the globe by establishing INTERCEPT as the standard of care, this quarter's commercial results are evidence of the progress we are making in multiple geographies and across our INTERCEPT product portfolio. The early launch and adoption of our next generation, LED-based INT200 illumination device continues to surpass our expectations around performance and customer experience, and advancements in our product development pipeline are encouraging, including the early resubmission for RBC CE Mark and the recent DoD award for the CRYO-First st...
|
|
|
22.07.25 - 22:21
|
Cerus Corporation to Release Second Quarter 2025 Financial Results on August 5, 2025 (Business Wire)
|
|
|
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2025 financial results will be released on Tuesday, August 5, 2025, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company's financial results and provide a general business overview and outlook.
To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event.
A replay will be available on Cerus' website and will be available approximately three hours after the call through August 26, 2025.
ABOUT CERUS
Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Co...
|
|
|
21.07.25 - 14:36
|
Cerus Corporation Announces Additional Department of Defense Award to Advance Care for Major Hemorrhage in Traumatic Injury (Business Wire)
|
|
|
Additional Funding to Support Randomized Study Evaluating Earlier Access to INTERCEPT Fibrinogen Complex in Trauma Associated Hemorrhagic Shock PatientsCONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that it has been awarded an additional $7.2 million contract amendment by the U.S. Department of Defense (DoD) Industrial Base Analysis and Sustainment (IBAS) program for the development of lyophilized Pathogen Reduced, Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex, or IFC, and, as lyophilized, LyoIFC) to treat bleeding due to trauma. This additional award is additive to the approximately $18 million currently provided for under Cerus' contract with the DoD to develop a manufacturing capability to provide a room-temperature, shelf-stable LyoIFC for use in austere military environments where refrigeration is limited or not feasible to improve the care of both military and civilian patients with traumatic injury.
The additional fund...
|
|
|
|
|
|
|
01.05.25 - 22:03
|
Cerus Corporation Announces First Quarter 2025 Financial Results (Business Wire)
|
|
|
First quarter 2025 Product Revenue of $43.2 Million, Up 13% Over Prior Year
Reiterating Full-Year 2025 Product Revenue Guidance Range of $194 - $200 Million
First Quarter 2025 Total Revenue of $48.9 Million Including Government Contract Revenue of $5.6 Million
Conference Call Today at 4:30 pm ET
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for the first quarter ended March 31, 2025, and provided a business update.
“We are off to a strong start in 2025, executing against our stated goals and making meaningful progress in advancing Cerus' mission to transform the safety and availability of transfused blood components,” said William “Obi” Greenman, Cerus' president and chief executive officer. “We delivered 13% first quarter product revenue growth, in-line with our Q1 guidance, received CE Mark for the INT200, our next generation LED-based illumination device ahead of plan, and most recently, we have submitted our updated CE Mark application...
|
|
|
|
|
17.04.25 - 14:33
|
Cerus Corporation to Release First Quarter 2025 Financial Results on May 1, 2025 (Business Wire)
|
|
|
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2025 financial results will be released on Thursday, May 1, 2025, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook.
To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event.
A replay will be available on Cerus' website and will be available approximately three hours after the call through May 22, 2025.
ABOUT CERUS
Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquarte...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
